A novel intergenic region (chr2: 30,193,816)-ALK fusion shows sensitivity to Alectinib in lung adenocarcinoma

被引：0
|
作者：
Ting Wang
Ge Du
Man Niu
Rui Liu
机构：
[1] Xi’an People’s Hospital (Xi’an No.4 Hospital),Department of Respiratory Medicine
[2] Beijing Rehabilitation Hospital Affiliated to Capital Medical University,Department of Rehabilitation Center for Elderly
[3] Xi’an People’s Hospital (Xi’an No.4 Hospital),Department of Pathology Medicine
来源：
BMC Pulmonary Medicine | / 23卷
关键词：
Anaplastic lymphoma kinase; Intergenic; Lung cancer; Case report;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] A novel intergenic region (chr2: 30,193,816)-ALK fusion shows sensitivity to Alectinib in lung adenocarcinoma
    Wang, Ting
    Du, Ge
    Niu, Man
    Liu, Rui
    [J]. BMC PULMONARY MEDICINE, 2023, 23 (01)
  • [2] A Novel Intergenic Region (chr2: 30,316,870)-ALK Fusion in a Patient with Lung Adenocarcinoma Responding to Crizotinib Combined with Pemetrexed Treatment: A Case Report
    Zhou, Danfei
    Ying, Jun
    Hu, Shanshan
    Li, Jiangdong
    Liu, Haijian
    [J]. ONCOTARGETS AND THERAPY, 2024, 17 : 261 - 265
  • [3] Chr2 30297612-ALK, A Novel Intergenic Fusion With Exon18 of ALK, Responds to Crizotinib
    Chen, Xiaofeng
    Zhao, Guohong
    Zhong, Peilin
    Zhang, Min
    Chen, Rongrong
    Zhang, Derong
    [J]. CLINICAL LUNG CANCER, 2020, 21 (06) : E564 - E566
  • [4] A novel intergenic (between REG3A and CTNNA2-AS1)-ALK fusion responds to alectinib in lung adenocarcinoma
    Liu, Zhenkun
    Wu, Qiang
    Li, Wen
    Li, Pengfei
    Huang, Lin
    Wang, Ting
    Zhou, Qinghua
    [J]. LUNG CANCER, 2023, 186
  • [5] A Novel LINC00478/LINC01549 Intergenic Region-ALK Fusion Responded Well to Alectinib in a Patient With Lung Adenocarcinoma
    Peng, Wei
    Li, Si
    Li, Lijian
    Xiao, Mingzhe
    Zhong, Jincai
    [J]. JTO CLINICAL AND RESEARCH REPORTS, 2021, 2 (01):
  • [6] Novel HIVEP1-ALK fusion in a patient with lung adenocarcinoma demonstrating sensitivity to alectinib: a case report
    Gu, Xiaodong
    Wang, Wenxian
    Wu, Wei
    Zhang, Yiping
    Shao, Lan
    Santarpia, Mariacarmela
    Christopoulos, Petros
    Myall, Nathaniel J.
    Shi, Zhiyong
    Lou, Guangyuan
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2022, 11 (05) : 902 - 909
  • [7] A novel SLC8A1-ALK fusion in lung adenocarcinoma confers sensitivity to alectinib: A case report
    Deng, Ling
    Tian, Panwen
    Qiu, Zhixin
    Wang, Ke
    Li, Yalun
    [J]. OPEN LIFE SCIENCES, 2022, 17 (01): : 846 - 850
  • [8] A novel intergenic region ALK fusion is targetable by alectinib in a non-small cell lung cancer patient with brain metastasis
    Cheng, Wanwan
    Qian, Chunfa
    Zhang, Haitao
    Meng, Qi
    Yin, Jiani C.
    Fang, Shencun
    [J]. ANTI-CANCER DRUGS, 2022, 33 (10) : 1182 - 1185
  • [9] Coexistence of a novel RGS18 downstream intergenic region ALK fusion and a THUMPD2-ALK fusion in a lung adenocarcinoma patient and response to crizotinib
    Wang, Yan-li
    Wu, Zhen-zhen
    Zhang, Heng-rui
    Chen, Dong-sheng
    Zhao, Xin
    [J]. LUNG CANCER, 2021, 154 : 216 - 218
  • [10] A novel EML4-ALK BIRC6-ALK double fusion variant in lung adenocarcinoma confers sensitivity to alectinib
    Zhong, Jiang-Ming
    Zhang, Gui-Feng
    Lin, Li
    Li, De-Yu
    Liu, Zhen-Hua
    [J]. LUNG CANCER, 2020, 145 : 211 - 212
12345